Market Research Report
Global Hemophilia A Therapeutics Market 2019-2023
|Published by||TechNavio (Infiniti Research Ltd.)||Product code||759931|
|Published||Content info||120 Pages
Delivery time: 1-2 business days
|Global Hemophilia A Therapeutics Market 2019-2023|
|Published: December 7, 2018||Content info: 120 Pages||
Emerging novel convenient approaches to drive market growth. Several novel therapies are emerging in the global hemophilia A therapeutics market. These therapies offer long lasting therapeutics benefits and some of the m possess potential to cure this disorder. Technavio's analysts have predicted that the hemophilia A therapeutics market will register a CAGR of almost 7% by 2023.
Hemophilia A is a rare genetic disorder, and the incidence of this disorder is gradually increasing. Hemophilia A accounts for about 80% of cases globally and mainly affects men.
High costs associated with drugs that treat hemophilia A are one of the biggest challenges faced by the market.
For the detailed list of factors that will drive and challenge the growth of the hemophilia A therapeutics market during the 2019-2023, view our report.
The market appears to be fragmented and with the presence of several companies including Pfizer and Shire the competitive environment is quite intense. Factors such as the emerging novel convenient approaches and the rising prevalence of hemophilia A, will provide considerable growth opportunities to hemophilia A therapeutics manufactures. Bayer, CSL, Novo Nordisk, Pfizer, and Shire are some of the major companies covered in this report.